BioMarin Pharmaceuticals (BMRN) Misses Q4 EPS by 12c; Guides FY12 Revs Below
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $65.68 --0%
Revenue Growth %: +32.7%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
OCCI, VIVO, PMCB, More
Revenue Growth %: +32.7%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
OCCI, VIVO, PMCB, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q4 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $107.9 million versus the consensus estimate of $115.3 million.
Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Oracle’s Ellison cancels plan to sell up to 50 mln shares
- UBS Starts Kalyan Jewellers India Ltd (KALYANKJ:IN) at Buy
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
